Abstract
Considered as the second men cancer in Algeria, prostate cancer is treated in 70% by radiation. That's why radiation therapy is therapeutic weapon for prostate cancer. Conformational Radiotherapy in 3D is the most common technique [1−5]. The use of conventionally optimized treatment plans was compared at case scenario of optimized treatment plans VMAT for prostate cancer. The evaluation of the two optimizations strategies focused on the resulting plans ability to retain dose objectives under the influence of patient set up. Dose Volume Histogram in the Planning Target Volume and dose in the Organs At Risks were used to calculate the conformity index, and evaluation ratio of irradiated volume which represent the main tool of comparison [6,7]. The situation was analysed systematically. The 14% dose increase in the target leads to a decrease in the dose in adjacent organs with 39% in the bladder. Therefore, the criterion for better efficacy and less toxicity reveal that VMAT is the best choice.
Highlights
Cancer is a term used when abnormal cells divide without control and are able to invade other tissues
Dose distribution illustrated by Dose Volume Histograms (DVHs) curves for patient treated for prostate cancer: (Right) VMAT plan, RC3D plan
The DVHs curves obtained by VMAT are underneath those obtained by RC3D
Summary
Cancer is a term used when abnormal cells divide without control and are able to invade other tissues. In this case, cells can spread to other parts of the body through the blood and lymphatic systems. The treatment of cancer is summarized in three main categories: drugs, surgery and radiation-therapy. The choice of the treatment depends on the tumor type, location, stage of the disease and general state of patient. Its ultimate goal is to eradicate the disease, without damaging the surrounding healthy tissues. The medical decision is always a trade-off and compromise between Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP) [3, 5, 8−10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
